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Abstract
Background: Bcl-2 promotes cell survival by inhibiting adapters needed for the activation and cleavage of caspases 
thus blocking the proteolytic cascade that ultimately dismantles the cell. Bcl-2 has been investigated as a prognostic 
factor in non small cell lung cancer (NSCLC) patients with conflicting results.
Methods: Here, we quantitatively assessed Bcl-2 expression in two large and independent cohorts to investigate the 
impact of Bcl-2 on survival. AQUA®, a fluorescent-based method for analysis of in situ protein expression, was used to 
measure Bcl-2 protein levels and classify tumors by Bcl-2 expression in a cohort of 180 NSCLC patients. An independent 
cohort of 354 NSCLC patients was used to validate Bcl-2 classification and evaluate outcome.
Results: Fifty % and 52% of the cases were classified as high expressers in training and validation cohorts respectively. 
Squamous cell carcinomas were more likely to be high expressers compared to adenocarcinomas (63% vs. 45%, p = 
0.002); Bcl-2 was not associated with other clinical or pathological characteristics. Survival analysis showed that patients 
with high BCL-2 expression had a longer median survival compared to low expressers (22 vs. 17.5 months, log rank p = 
0.014) especially in the subset of non-squamous tumors (25 vs. 13.8 months, log rank p = 0.04). Multivariate analysis 
revealed an independent lower risk for all patients with Bcl-2 expressing tumors (HR = 0.53, 95% CI 0.37-0.75, p = 
0.0003) and for patients with non-squamous tumors (HR = 0.5, 95% CI 0.31-0.81, p = 0.005).
Conclusions: Bcl-2 expression defines a subgroup of patients with a favorable outcome and may be useful for 
prognostic stratification of NSCLC patients.
Background
Bcl-2 is a key regulator of the mitochondrial apoptotic
pathway promoting survival by inhibition of adapters
necessary for the activation and cleavage of caspases [1-
4]. It is the balance and competitive dimerization
between anti-apoptotic (Bcl-2, Bcl-XL, Bcl-W, Mcl-1, A1)
and pro-apoptotic (Bax, Bak, Bad, Bid) Bcl-2 family mem-
bers that determines cell fate and regulates the response
to apoptotic signals [2,5,6]. Some tumors evade apoptosis
and obtain a survival advantage through aberrant Bcl-2
expression and the oncogenic potential of Bcl-2 is well
documented in follicular lymphomas [7]. Bcl-2 has been
found to induce tumor growth and confer resistance to
chemotherapeutic agents in xenograft models of human
non small cell lung cancer (NSCLC) [8-10] and Bcl-2
inhibition seems to contribute to reversal of drug resis-
tance in a variety of cancer cell line models[11,12]. Dem-
* Correspondence: valsamo.anagnostou@yale.edu
1 Department of Pathology, Yale University School of Medicine, New Haven, CT, 
USA
Full list of author information is available at the end of the articleAnagnostou et al. BMC Cancer 2010, 10:186
http://www.biomedcentral.com/1471-2407/10/186
Page 2 of 11
onstration of the role of Bcl-2 in oncogenesis has
prompted the development of drugs targeting Bcl-2 for
degradation[13]. Despite the promising preclinical stud-
ies supporting a critical role of Bcl-2 in chemoresistance,
addition of anti-Bcl-2 antisense oligonucleotide therapies
to standard chemotherapy was not correlated with a sur-
vival benefit [14-18].
Bcl-2 has been found to be upregulated in a series of
tumor types including squamous cell carcinomas of the
lung and the potential of Bcl-2 to predict survival for
NSCLC patients has been assessed by immunohis-
tochemistry, with different studies demonstrating varying
degrees of correlation between Bcl-2 expression and out-
come [19-28]. A meta-analysis of 28 clinical studies
showed that Bcl-2 positivity was associated with
improved survival with a combined hazard of 0.71[22],
however numerous individual studies suggest that Bcl-2
has no prognostic value for NSCLC [20,21,27-31] while
others report a correlation with poor prognosis [32-36].
These conflicting observations are mainly attributed to
small sample size, different immunohistochemical tech-
niques and qualitative scoring systems for Bcl-2 expres-
sion, lack of reproducibility and most importantly lack of
independent validation of the results. Here we studied the
l e v e l  o f  B c l - 2  e x p r e s s i o n  i n  l u n g  c a n c e r  p a t i e n t s  a n d
assessed its prognostic impact on a large cohort of pri-
m a r y  N S C L C ;  o u r  f i n d i n g s  w e r e  t h e n  v a l i d a t e d  i n  a n
independent cohort of 354 NSCLC patients from another
continent.
Methods
Cohorts
Formalin-fixed paraffin-embedded primary NSCLC
tumors from 180 patients that underwent surgery at Yale
University/New Haven Hospital between January 1995
and May 2003 were obtained from the archives of the
Pathology Department of Yale University (New Haven,
CT). The Yale University cohort consisted of 92 (51%)
men and 88 (49%) women with median age of 65 years.
Data on stage according to TNM system and differentia-
tion and histological type according to the World Health
Organization (WHO) classification for NSCLC[37] is
shown in Table 1. All patients were treatment-naïve prior
to tumor resection (or acquisition of surgical biopsies for
stage IV patients); average follow-up time was 39.32 ± 2.2
months (median 27.3, range 0.1-182). In parallel, we
assessed a retrospectively collected, independent cohort
of 354 NSCLC patients diagnosed between 1991 and
2001, obtained from the Pathology Departments of
Sotiria General Hospital (Athens, Greece) and Patras
University General Hospital (Rion, Greece). This cohort
consisted of 290 (82%) men and 42 (12%) women with
median age of 64 years. Details on stage, differentiation
and histological type are shown in Table 1. Three hun-
dred and forty three patients had undergone complete
surgical resection for NSCLC and 343 patients received
no chemotherapy or radiation prior to resection. Average
duration of follow up in this cohort was 24.8 ± 1.1 months
(median 20, range 0.1-223). The study was approved by
the institutional review boards of all centers. Written
informed consent was obtained for each case prior to
inclusion in the study.
Tissue Microarrays (TMAs)
Tissue specimens were prepared in a tissue microarray
(TMA) format: representative tumor areas were obtained
from formalin fixed paraffin embedded specimens of the
primary tumor and two 0.6 mm cores from each tumor
block were arrayed in a recipient block. Formalin fixed
paraffin embedded cell line pellets were used as controls
on a smaller specialized TMA (control array): BT-20,
MB175, T47D, HT29, SW-480, H1666, SKBR3, MB453,
H2126, SKOV3, HCC2279, A431, MB231, MB435,
MB436, SUM159, BT474, MCF7 and ZR-751 were pur-
c h a s e d  f r o m  t h e  A m e r i c a n  T y p e  C u l t u r e  C o l l e c t i o n
(Manassas, VA) or donated by other labs. Culture condi-
tions and cell-line TMA construction have been pub-
lished in detail elsewhere [38].
Antibodies and Immunohistochemistry
The arrays were deparaffinized with xylene, rehydrated
and antigen-retrieved by pressure cooking for 15 minutes
in 10 mM Tris/1 mM EDTA buffer (pH = 9). Slides were
pre-incubated with 0.3% bovine serum albumin (BSA) in
0.1 M tris-buffered saline (TBS, pH = 8) for 30 minutes at
room temperature. Slides were then incubated with a
cocktail of the Bcl-2 primary antibody (mouse monoclo-
nal, clone 124, Dako, Carpinteria, CA) and a wide-spec-
trum rabbit anti-cow cytokeratin antibody (Z0622, Dako,
Carpinteria, CA) both diluted 1:100 in BSA/TBS over-
night at 4°C. This was followed by an 1-hour incubation
with Alexa 546-conjugated goat anti-rabbit secondary
antibody (A11010, Molecular Probes, Eugene, OR)
diluted 1:100 in mouse EnVision reagent (K4001, Dako,
Carpinteria, CA). Cyanine 5 (Cy5) directly conjugated to
tyramide (FP1117, Perkin-Elmer, Boston, MA) at a 1:50
dilution was used as the fluorescent chromagen for target
detection. Prolong mounting medium (ProLong Gold,
P36931, Molecular Probes, Eugene, OR) containing 4',6-
Diamidino-2-phenylindole (DAPI) was used to identify
tissue nuclei. Lymphoid tissue was used as positive con-
trol as indicated by the manufacturer. Negative control
sections, in which the primary antibody was omitted,
were used for each immunostaining run.
Standardization
Serial sections of a smaller specialized TMA (control
array) were stained aside both cohorts to confirm assay
reproducibility; this allows for the construction of a nor-Anagnostou et al. BMC Cancer 2010, 10:186
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Table 1: Clinical characteristics and BCL-2 expression for the training and validation cohorts.
N( % ) B C L - 2
(mean ± SE)
p value* N (%) BCL-2
(mean ± SE)
p value*
All 180 100 354 100
Age† 64.3 ± 0.8 62.3 ± 0.5
Sex
Male 92 51 44.3 ± 7.7 0.15 290 82 23.72 ± 2.6 0.16
Female 88 49 68.5 ± 15.2 42 12 32.29 ± 2
Missing - 22 6
Stage
I 90 50 57.9 ± 11.6 0.39 107 30 30 ± 3.1 0.8
II 27 15 54.5 ± 21 90 25 30.1 ± 3.2
III 37 21 54.4 ± 21 95 27 32.5 ± 3.7
IV 16 9 18.7 ± 1.2 38 11 26.7 ± 5
Missing 10 5 24 7
Differentiation
High 12 7 27.1 ± 5.3 0.22 23 7 27.6 ± 5.4 0.11
Moderate 44 24 63 ± 18.7 138 39 26.32 ± 2
Low 70 40 39.9 ± 7.8 168 48 34.13 ± 3
Missing 54 29 25 6Anagnostou et al. BMC Cancer 2010, 10:186
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malization standard curve to adjust for run to run vari-
ability. Nineteen cell line formalin fixed paraffin pellets
were used as controls and 30 NSCLC patient cases were
also included on the control TMA to supplement the cell
line controls, those index cases display much higher cut-
to-cut and core-to-core reproducibility.
AQUA®
Automated Quantitative Analysis (AQUA) allows exact
measurement of protein concentration within subcellular
compartments, as described in detail elsewhere[39]. In
brief, a series of high resolution monochromatic images
were captured by the PM-2000™ microscope (HistoRx,
New Haven, CT). For each histospot, in- and out-of-focus
images were obtained using the signal from the DAPI,
cytokeratin-Alexa 546 and Bcl-2-Cy5 channel. Bcl-2 was
measured using a channel with emission maxima above
620 nm, in order to minimize tissue autofluorescence.
Tumor was distinguished from stromal and non-stromal
elements by creating an epithelial tumor "mask" from the
cytokeratin signal. This created a binary mask (each pixel
being either "on" or "off") on the basis of an intensity
threshold set by visual inspection of histospots. AQUA
score of Bcl-2 in each subcellular compartment was cal-
culated by dividing the Bcl-2 compartment pixel intensi-
ties by the area of the compartment within they were
measured. AQUA scores were normalized to the expo-
sure time and bit depth at which the images were cap-
tured, allowing scores collected at different exposure
times to be directly comparable.
Statistical analysis
Pearson's correlation coefficient (R) was used to assess
the correlation between AQUA scores from redundant
tumor cores as well as the same cores on serial cuts of the
control array. An R2 greater than 0.4 was indicative of
good inter- and intra-array reproducibility and thus the
average values for Bcl-2 AQUA scores from duplicate
samples were calculated and treated as independent con-
tinuous variables. Analysis of variance (ANOVA) was
used to compare continuous AQUA scores among groups
with different clinical/pathologic characteristics and chi
square was employed for comparison of binarized Bcl-2
AQUA scores between adenocarcinomas and squamous
cell carcinomas. X-tile software[40] was used to select the
optimal Bcl-2 concentration cutpoint for the Yale Univer-
sity cohort (training set); this cutpoint was subsequently
validated in the Greek Lung Cancer cohort (validation
set). Survival curves for the validation set were con-
structed using the Kaplan-Meier method and survival dif-
ferences were analyzed by the log rank test. Cox
proportional hazards regression analysis was used to
determine which independent factors jointly had a signif-
icant impact on overall survival. All p values were based
Histology
Adenocarcinoma 111 62 41.9 ± 8.7 0.49 134 38 24.5 ± 2.2 0.07
Squamous cell 
carcinoma
37 21 57.9 ± 19.5 161 46 35 ± 2.8
Large cell 
carcinoma
11 6 85.5 ± 45 5 1 30.4 ± 11.2
Adenosquamous 
carcinoma
13 7 37.8 ± 18.4 4 1 25.1 ± 6.7
Giant cell 
carcinoma
-1 7 5 2 7  ±  6 . 6
Various 8 4 10 3
Missing - 23 6
Abbreviations: SE; standard error
*p is given for t-test for comparison of continuous BCL-2 AQUA scores between 2 groups and for Analysis of Variance (ANOVA) for comparisons 
among more than 3 groups
†Mean value and standard error of the mean are displayed for age in both cohorts
Table 1: Clinical characteristics and BCL-2 expression for the training and validation cohorts. (Continued)Anagnostou et al. BMC Cancer 2010, 10:186
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on two-sided testing and differences were considered sig-
nificant at p  < 0.05. All statistical analyses were done
using the SPSS software program (version 13.0 for Win-
dows, SPSS Inc., Chicago, IL).
Results
Assay reproducibility and assessment of Bcl-2 in NSCLC and 
cell line controls
Evaluation of the inter-array reproducibility for antibody
validation did not reveal significant differences between
serial sections of the control array (Pearson's R = 0.96, p <
0.0001; Figure 1A). Bcl-2 AQUA scores for specimens on
the validation cohort were converted according to the cell
line standard curve (y = 0.3197x+8.8; Figure 1A), in order
to normalize for run to run variability. Bcl-2 was predom-
inantly expressed in the cytoplasm of cell lines (Figure
1B-C) as well as NSCLC tumor cells (Figure 2) and this
cytoplasmic pattern is consistent with its localization in
the inner mitochondrial membrane [41]. SKBR3, a known
low Bcl-2 expressing breast cancer cell line Bcl-2[42] had
an AQUA score of 18, whereas MCF7 and BT474 that are
high Bcl-2 expressers [42] showed the highest AQUA
scores for Bcl-2 expression (Figure 1B-C).
To assess intra-tumor heterogeneity for Bcl-2 expres-
sion, we compared AQUA scores from redundant tumor
cores and observed significant correlation (Pearson's R =
0.85, p < 0.0001; Figure 1D and Pearson's R = 0.94, p <
0.0001 for the training and validation cohort respec-
tively). Therefore, AQUA scores in the tumor "mask"
were averaged between redundant histospots and final
scores ranged from 7.7 to 800 (mean 56 ± 8.4, median
18.8) and from 11.6 to 227 (mean 30 ± 1.7, median 19) for
the training and validation set. Specimens with less that
5% tumor area per spot were not included in automated
quantitative analysis for not being representative of the
corresponding tumor specimen.
Optimal cut point selection for BCL-2 expression
We applied X-tile[40] in order to determine the optimal
cutpoint of continuous Bcl-2 AQUA scores; this statisti-
ca l  m e t h od  as s es s es  ev e ry  d i vis i o n  o f  c o n t i n u o us  va ri -
ables into ordinal classes and performs standard Monte
Carlo simulations to produce chi squared values which
can be maximized to find the optimal cut point in contin-
uous data. Since it is not statistically valid to test multiple
divisions with corrections for multiple sampling, rigorous
statistical evaluation is achieved by defining divisions in a
training set and then validating them in an independent
non-overlapping validation set. On that basis we used the
Yale University Cohort as a training set to generate a cut-
point that provides the optimal separation in terms of
survival - an AQUA score of 18.8 was thus selected- and
validated this cutpoint on the Greek Lung Cancer Cohort
(validation set).
Patient characteristics and correlation with Bcl-2 
expression
C l i n i c a l  a n d  p a t h o l o g i c  p a r a m e t e r s  t h a t  w e r e  a n a l yz e d
included age, gender, histological type, tumor differentia-
tion and stage. In the training cohort, Bcl-2 expression
was identified in 90 (50%) of NSCLCs, including 51 (46%)
adenocarcinomas (AC), 23 (62%) squamous cell carcino-
mas (SCC), 5 (45%) large cell carcinomas (LCC) and 6
(46%) adenosquamous carcinomas (AS). No significant
difference in continuous Bcl-2 scores was found among
different histological subgroups (mean AQUA scores ±
standard error-SE 41.9 ± 8.7, 57.9 ± 19.5, 85.5 ± 45 and
37.8 ± 18.4 for AC, SCC, LCC and AS respectively,
ANOVA p = 0.49; Table 1); however when scores were
binarized by the optimal cutpoint (AQUA score 18.8) we
observed higher Bcl-2 expression in SCC compared to
AC (62% vs. 46%, chi square p = 0.08). Bcl-2 was not sig-
nificantly associated with any other clinicopathological
characteristic (Table 1).
In the validation cohort, high BCL-2 expression was
observed in 186 (52%) patients: 60 (45%) AC, 101 (63%)
SCC, 2 (40%) LCC and 2 (50%) AS were classified as high
expressers. Comparison of continuous BCL-2 scores
among different histological subgroups revealed higher
BCL-2 expression in the SCC group (mean AQUA scores
± SE, 24.5 ± 2.2, 35 ± 2.8, 30.4 ± 11.2, 25.1 ± 6.7 and 27 ±
6.6 for AC, SCC, LCC and AS respectively, ANOVA p =
0.07; Table 1); this was more evident for binarized BCL-2
AQUA scores (63% BCL-2 positive SCC vs. 45% BCL-2
positive AC, chi square p = 0.002). No significant correla-
tion was found between BCL-2 expression and gender,
age, stage or tumor differentiation (Table 1).
Correlation of Bcl-2 with survival (training cohort)
NSCLC patients classified as high Bcl-2 expressers (n =
90) had a better prognosis compared to the low express-
ing group (median survival 38.7 vs. 24.37 months; Figure
3A). Cox univariate analysis with binarized Bcl-2 scores
revealed that high Bcl-2 expression resulted in 41%
reduction in risk for all NSCLC patients (hazards ratio-
HR = 0.59, 95% confidence interval-CI 0.4-0.87, p =
0.009). A subgroup analysis of non squamous tumors
yielded similar results; high Bcl-2 expressers (n = 67)
showed a longer survival (median survival 31.92 vs. 23.62
months for the high and low group respectively; Figure
3B) and a 44% reduction in risk for death (HR = 0.56, 95%
CI 0.35-0.89, p = 0.014). The small number of SCC
patients did not allow us to perform meaningful survival
analysis for that group.
Validation of cutpoint selection (validation cohort)
The cutpoint generated from the training set was applied
in the validation cohort and we subsequently assessed the
potential of Bcl-2 to predict survival; among all patientsAnagnostou et al. BMC Cancer 2010, 10:186
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tumors with high Bcl-2 expression (n = 186) had a higher
median survival compared to the low Bcl-2 expressers
(median survival 22 vs. 17.5 months respectively, log rank
p = 0.014; Figure 3C). Cox univariate analysis with con-
tinuous Bcl-2 scores binarized by the optimal cutpoint
showed that high Bcl-2 expression resulted in 33% reduc-
tion in risk (HR = 0.67, 95% CI 0.49-0. 29, p = 0.016) for
all patients of the validation cohort. The same trend was
observed in a subgroup analysis for non squamous
tumors: high Bcl-2 expressers (n = 76) had a significantly
better outcome compared to the low Bcl-2 group (median
survival 25 vs. 13.8 months, log rank p = 0.04; Figure 3D)
and Bcl-2 expression was associated with a 37% reduction
in risk (HR = 0.63, 95% CI 0.4-0.98, p = 0.04). Interest-
ingly no survival benefit was found for the high express-
ing Bcl-2 squamous cell carcinomas (median survival 26
vs. 21 months for the high and low expressers respec-
tively; log rank p = 0.3; data not shown).
Assessment of the independent potential of Bcl-2 to 
predict survival
Multivariate Cox proportional hazards regression analy-
sis was performed to derive risk estimates related to sur-
vival for age, gender, stage, tumor differentiation,
histological type and Bcl-2 expression; cases with missing
values were excluded from analysis (Table 2). Age, stage
and Bcl-2 expression were significantly associated with
survival and Bcl-2 expression retained its prognostic
value such that NSCLC patients with high Bcl-2 expres-
sion had a 47% reduction in risk (HR = 0.53, 95% CI 0.37-
0.75, p = 0.0003; Table 2). In a subgroup analysis of non
squamous tumors, high Bcl-2 expression significantly
contributed to the prognostic value of the model reveal-
ing the independent favorable prognostic value of Bcl-2
(HR = 0.5, 95% CI 0.31-0.81, p = 0.005; Table 2). Gender,
stage, histological type and tumor differentiation were
analyzed as categorical and age as continuous variables.
Discussion
Despite the large number of studies the value of Bcl-2 for
predicting outcome for NSCLC remains controversial.
Meta-analysis of 13 immunohistochemical studies assess-
ing Bcl-2 with the same antibody clone as used in this
study revealed that Bcl-2 was associated with better sur-
vival for NSCLC patients (HR = 0.71, 95% CI 0.61-0.83)
however this study was biased in favor of positive trials
[22]. Bcl-2 has also been reported to be a negative prog-
nostic marker [32,33,35,36,43] whereas the majority of
studies on Bcl-2 expression show no impact on survival
Figure 1 Distribution and reproducibility of Bcl-2 AQUA scores in cell lines and training set. A. Plotting AQUA scores of the same histospots on 
serial cuts of the control array stained aside the 2 cohorts at different runs provided a standard curve in order to normalize for run to run variability 
(Pearson's R = o.96 between runs, p < 0.0001) B. Distribution of Ncl-2 AQUA scores in 19 cell line controls embedded in the control TMA C. Represen-
tative immunofluorescence staining in a high (MCF7) and low (SKBR3) Bcl-2 expressing breast cancer cell lines; AQUA scores are displayed in insets D. 
Linear regression between Bcl-2 AQUA scores of redundant tumor cores reveals significant correlation (Pearson's R = 0.85, p < 0.0001).Anagnostou et al. BMC Cancer 2010, 10:186
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[20,21,27,28]. Methodology differences in immunohis-
tochemistry, different thresholds for Bcl-2 and use of
conventional semi-qualitative, subjective pathologist-
scoring systems, lack of reproducibility and lack of inde-
pendent validation of the results preclude firm conclu-
sions based on the current literature. The goal of this
work was to quantitatively and objectively assess Bcl-2
expression in NSCLC to determine its prognostic value.
Bcl-2 expression has been confirmed in 20% to 58% of
NSCLC and 32% to 69.4% of squamous cell carcinomas of
the lung [19,22,28] and this is consistent with our findings
of 50% and 51% Bcl-2 positive NSCLC tumors and 62%
and 63% positive squamous cell carcinomas for the train-
ing and validation cohorts respectively. Bcl-2 has been
found to mediate the anti-apoptotic effect of nicotine in
lung cancer [44] and we observed higher Bcl-2 expression
in tumors of smokers (n = 265) compared to non smokers
(n = 29; mean ± SE 30.8 ± 2.1 and 22.7 ± 2.96 respectively;
data not shown) however this did not reach statistical sig-
nificance due to small number of non smokers.
Given the known anti-apoptotic role of the Bcl-2 one
would expect that high Bcl-2 expression would confer to
a worse prognosis, rather than a prolonged survival. One
possible explanation is that Bcl-2 has a cell cycle inhibi-
tory effect genetically separable from its survival function
that could potentially reduce its oncogenic impact [45]. It
is possible that the effect of Bcl-2 on apoptosis is coun-
tered by other oncogenes (like p53); apoptosis in lung
cancer could thus occur independently without being pri-
marily modulated by Bcl-2. Both proapoptotic and anti-
apoptotic Bcl-2 family proteins are known to change their
respective phenotypes in certain scenarios and Bcl-2
appears to have normal cellular functions that promote
cell survival [46]. Although Bcl-2 is typically considered
to inhibit caspase activation, it can also serve as a down-
stream "death substrate" converted by caspases to a Bax-
like effector and activation of its BH3 homology domain
not only inactivates the antiapoptotic activity of Bcl-2 but
also releases a potent proapoptotic fragment [47]. In data
not shown, we have found a correlation between Bcl-2
and cleaved caspase 3 expression (Spearman rho = 0.147,
p = 0.049) and this is consistent with the existence of a
feedback loop between Bcl-2 and caspases, allowing the
latter to bypass Bcl-2 inhibition. Thus, Bcl-2 may play
opposing roles in apoptosis regulation depending on cel-
lular context.
Accurate measurement of Bcl-2 in NSCLC has been
historically difficult due to subjective and qualitative
methodology complicated by lack of standardization
between studies. Here, we employed AQUA[39], a fully
quantitative method to calculate Bcl-2 concentration
within subcellular compartments and construct a cell
line-based standard curve in order to normalize for run
to run variability. Furthermore, the controversial impact
of Bcl-2 on survival can be partially attributed to the dif-
ferent and often un-justified cut-off points used to clas-
sify NSCLC tumors for Bcl-2 positivity. In order to
overcome bias related to any single a priori cutpoint
selection we used X-tile[40] to assess every division of
continuous Bcl-2 scores into ordinal classes and generate
a cutpoint that provides the optimal classification in
terms of survival; interestingly the cut point selected was
the median Bcl-2 AQUA score of the training set. How-
ever, since we had no a priori biological reason to select
the median as the cut-point, we used the training set
cohort to prevent operator bias in cut-point selection.
This rigorous statistical approach demands independent
validation of the results; therefore we validated the prog-
nostic classification generated in an independent NSCLC
cohort from a separate institution.
A potential limitation of this study is the retrospective
nature of the collection of both cohorts; a prognostic trial
of a single marker such as this can rarely be prospectively
designed outside the setting of a clinical trial. Further-
more, the 2 cohorts are not well matched in terms of gen-
der and disease stage however we believe that the
similarity of the results in both cohorts suggests robust-
ness of the observation.
Figure 2 Automated Quantitative Analysis (AQUA) of Bcl-2 in 
lung cancer. (A-D) Tumor histospot corresponding to a NSCLC patient 
with Bcl-2 AQUA score of 400 A. Cytokeratin-Cy3 image used to identi-
fy tumor; the epithelial tumor "mask" is displayed in C B. Colocalization 
of subcellular compartments: the non nuclear (green) and nuclear 
(blue) compartment are defined by the cytokeratin and the DAPI signal 
respectively D. Bcl-2-Cy5 (red), cytokeratin (green) and DAPI (blue) co-
localization; Bcl-2 shows a representative cytoplasmic pattern; AQUA 
score is inset into the bottom right corner.Anagnostou et al. BMC Cancer 2010, 10:186
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S q u a m o u s  c e l l  c a r c i n o m a s  s e e m  t o  h a v e  a  d i s t i n c t
molecular background compared to non squamous
tumors [48] and this is also prominent in the clinical set-
ting, where squamous histology is an exclusion criterion
for bevacizumab [49,50] as well as pemetrexed treatment
[51]. We demonstrated a survival benefit for Bcl-2
expression in patients with non squamous histology
absent in squamous cell carcinomas and this observation
confirms the effect of histology for prognostic stratifica-
tion of NSCLC patients. Although we are optimistic that
the prognostic findings presented here are likely to por-
tend predictive results, it is not evident that Bcl-2 expres-
sion as a positive prognostic factor is related to a
beneficial therapeutic target potential [14-17]. The incon-
sistency between pre-clinical studies and clinical trials on
Bcl-2 inhibitors confirms the necessity of identifying bio-
markers capable of predicting which cancers would bene-
fit from treatment with Bcl-2 inhibitors [18]; whether
Bcl-2 expression itself has such a predictive value in non
squamous NSCLC remains to be determined.
Conclusions
The present study is the first one assessing Bcl-2 expres-
sion by a fully quantitative method and demonstrating
the impact of Bcl-2 on survival of NSCLC in 2 indepen-
dent cohorts. Our results indicate that loss of Bcl-2
expression is correlated with a more aggressive behaviour
of NSCLC tumors and high Bcl-2 expression defines a
subgroup of patients with a favourable outcome. Our val-
idated model may be useful for prognostic stratification
of lung cancer patients as well as incorporation of Bcl-2
into clinical decisions.
Figure 3 Disease outcome by Bcl-2 expression in NSCLC. A, B. Survival curves based on cohort division by the optimal cutpoint generated from 
the Yale University Cohort (training set); NSCLC and non squamous patients classified as high Bcl-2 expressers (n = 90 and n = 67 respectively) show 
a benefit towards survival. The distribution of AQUA scores is displayed in inset. C. Kaplan-Meier graphical analysis of survival in NSCLC of the Greek 
Lung Cancer Cohort (validation set, n = 354). Patients with a high Bcl-2 score (n = 186) had a significant higher median survival compared to the low 
Bcl-2 group (log rank p = 0.014). The distribution of Bcl-2 AQUA scores is displayed in inset. D. Survival curves for non squamous tumors of the valida-
tion cohort classified as high (n = 76) versus low Bcl-2 expressers showed a significant benefit towards survival for the high expressing group (log rank 
p = 0.04). AQUA; automated quantitative analysis.Anagnostou et al. BMC Cancer 2010, 10:186
http://www.biomedcentral.com/1471-2407/10/186
Page 9 of 11
Table 2: Multivariate analysis of overall survival for Bcl-2 expression in lung cancer patients of the validation cohort
Validation Cohort
All patients Non squamous
Characteristic HR (95% CI) p value* HR (95% CI) p value*
Age 1.02 (1-1.04) 0.02 1.03 (1-1.06) 0.04
Gender
Female 1
Male 0.72 (0.44-1.18) 0.19 0.6 (0.29-1.24) 0.17
Stage
Stage I 1 1
Stage II 1.9 (1.18-3) 0.008 2.2 (1.07-4.54) 0.03
Stage III 3 (1.9-4.6) < 0.001 3.6 (1.8-7.1) < 0.001
Stage IV 4.1 (2.4-7.02) < 0.001 5.1 (2.5-10.49) < 0.001
Histology
Adenocarcinoma 1
Squamous cell 
carcinoma
1.1 (0.76-1.6) 0.6
Large cell carcinoma 0.8 (0.19-3.46) 0.8
Adenosquamous 
carcinoma
0.9 (0.21-3.77) 0.9
Giant cell carcinoma 1.05 (0.46-2.41) 0.9
Various 1.5 (0.6-3.97) 0.4Anagnostou et al. BMC Cancer 2010, 10:186
http://www.biomedcentral.com/1471-2407/10/186
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